Organon & Co. $OGN Shares Acquired by Franklin Resources Inc.

Franklin Resources Inc. boosted its stake in Organon & Co. (NYSE:OGN) by 33.4% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 404,558 shares of the company’s stock after purchasing an additional 101,325 shares during the quarter. Franklin Resources Inc. owned about 0.16% of Organon & Co. worth $3,916,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of OGN. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Organon & Co. by 5.6% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 66,820 shares of the company’s stock valued at $995,000 after buying an additional 3,551 shares during the period. Federated Hermes Inc. grew its position in Organon & Co. by 10.9% during the first quarter. Federated Hermes Inc. now owns 83,942 shares of the company’s stock valued at $1,250,000 after acquiring an additional 8,265 shares during the period. Natixis Advisors LLC grew its position in Organon & Co. by 69.1% during the first quarter. Natixis Advisors LLC now owns 52,263 shares of the company’s stock valued at $778,000 after acquiring an additional 21,358 shares during the period. PNC Financial Services Group Inc. increased its stake in Organon & Co. by 1.0% during the first quarter. PNC Financial Services Group Inc. now owns 217,417 shares of the company’s stock worth $3,237,000 after acquiring an additional 2,074 shares during the last quarter. Finally, PARK CIRCLE Co raised its holdings in shares of Organon & Co. by 640.7% in the 1st quarter. PARK CIRCLE Co now owns 4,000 shares of the company’s stock worth $60,000 after purchasing an additional 3,460 shares during the period. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Organon & Co. Trading Down 1.5%

OGN opened at $7.49 on Wednesday. The firm’s 50 day moving average is $8.47 and its 200-day moving average is $9.26. Organon & Co. has a 52-week low of $6.18 and a 52-week high of $17.23. The company has a quick ratio of 1.20, a current ratio of 1.75 and a debt-to-equity ratio of 9.69. The firm has a market capitalization of $1.95 billion, a P/E ratio of 3.90, a P/E/G ratio of 1.63 and a beta of 0.57.

Organon & Co. (NYSE:OGN) last released its quarterly earnings results on Monday, November 10th. The company reported $1.01 earnings per share for the quarter, beating analysts’ consensus estimates of $0.93 by $0.08. Organon & Co. had a net margin of 7.95% and a return on equity of 143.47%. The business had revenue of $1.60 billion during the quarter, compared to analyst estimates of $1.57 billion. During the same period last year, the business earned $1.38 EPS. Analysts expect that Organon & Co. will post 3.68 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 11th. Stockholders of record on Thursday, November 20th will be paid a dividend of $0.02 per share. The ex-dividend date is Thursday, November 20th. This represents a $0.08 annualized dividend and a dividend yield of 1.1%. Organon & Co.’s dividend payout ratio (DPR) is currently 4.17%.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. Weiss Ratings reiterated a “sell (d+)” rating on shares of Organon & Co. in a report on Wednesday, October 8th. JPMorgan Chase & Co. reduced their price target on shares of Organon & Co. from $14.00 to $12.00 and set an “underweight” rating on the stock in a research report on Tuesday, November 11th. Piper Sandler lowered shares of Organon & Co. from an “overweight” rating to an “underweight” rating and set a $5.00 price objective for the company. in a research report on Monday, October 27th. Finally, Morgan Stanley cut their target price on shares of Organon & Co. from $10.00 to $9.00 and set an “equal weight” rating on the stock in a research note on Tuesday, November 11th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have given a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, Organon & Co. has a consensus rating of “Hold” and an average target price of $12.50.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.